Discover
Biotech CEO Sisterhood
Stealth BioTherapeutics' CEO Reenie McCarthy describes the fortitude and close relationship with a patient community that led to the first approved therapy for Barth Syndrome

Stealth BioTherapeutics' CEO Reenie McCarthy describes the fortitude and close relationship with a patient community that led to the first approved therapy for Barth Syndrome
Update: 2025-11-13
Share
Description
Interviewed by Sisterhood editorial board member Erika Smith, Reenie McCarthy discusses how working with the Barth Syndrome Community, an ultra rare disease, helped the company better understand outcomes that are important to daily life for these patients. She also highlights the role that mitochondria play in biology, and the future of treatments for diseases of mitochondrial dysfunction.
Comments
In Channel
00:00
00:00
x
0.5x
0.8x
1.0x
1.25x
1.5x
2.0x
3.0x
Sleep Timer
Off
End of Episode
5 Minutes
10 Minutes
15 Minutes
30 Minutes
45 Minutes
60 Minutes
120 Minutes






















